Showing results (101-110 of 116) with videos related to
Sort By:
Pageof 12
Leukemia|March 27, 2019
Short telomeres are associated with inferior outcome, genomic complexity, and clonal evolution in chronic lymphocytic leukemiaBilly Michael Chelliah Jebaraj, Eugen Tausch, Dan A Landau, et al.Haematologica|February 29, 2020
Bendamustine, followed by ofatumumab and ibrutinib in chronic lymphocytic leukemia (CLL2-BIO): primary endpoint analysis of a multicenter, open-label phase-II trialPaula Cramer, Julia V Tresckow, Sandra Robrecht, et al.The Lancet. Oncology|May 25, 2016
First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trialBarbara Eichhorst, Anna-Maria Fink, Jasmin Bahlo, et al.Blood|June 26, 2023
Final analysis of the CLL2-GIVe trial: obinutuzumab, ibrutinib, and venetoclax for untreated CLL with del(17p)/TP53mutHenriette Huber, Eugen Tausch, Christof Schneider, et al.Leukemia|February 20, 2020
Early treatment with FCR versus watch and wait in patients with stage Binet A high-risk chronic lymphocytic leukemia (CLL): a randomized phase 3 trialCarmen D Herling, Florence Cymbalista, Carolin Groß-Ophoff-Müller, et al.Blood|December 25, 2009
Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup studyChristiane Pott, Eva Hoster, Marie-Helene Delfau-Larue, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2018
Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal TrialStephan Stilgenbauer, Barbara Eichhorst, Johannes Schetelig, et al.Genes, Chromosomes & Cancer|November 3, 2019
Reconstruction of rearranged T-cell receptor loci by whole genome and transcriptome sequencing gives insights into the initial steps of T-cell prolymphocytic leukemiaPaurnima Patil, Agata Cieslak, Stephan H Bernhart, et al.Hemasphere|February 20, 2020
Long Term Follow-up Data and Health-Related Quality of Life in Frontline Therapy of Fit Patients Treated With FCR Versus BR (CLL10 Trial of the GCLLSG)Nadine Kutsch, Jasmin Bahlo, Sandra Robrecht, et al.Cytometry. Part a : the Journal of the International Society for Analytical Cytology|October 28, 2014
Quality assessment program for EuroFlow protocols: summary results of four-year (2010-2013) quality assurance roundsTomas Kalina, Juan Flores-Montero, Quentin Lecrevisse, et al.Pageof 12